Author

Elżbieta Patkowska

h-index 5 View on Semantic Scholar

We have 2 of 25 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study.

The phase 3, open-label LACEWING study evaluated efficacy and safety of the FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib (GIL) plus azacitidine (AZA) in newly diagnosed (ND) FLT3-mutated (FLT3mut+) acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy (IIC). Patients were enrolled int...

E. Wang, P. Montesinos, M. Minden et al. · Haematologica · 1 citation · ⚡1

Open access Aug 2026

mTORC1 inhibition upregulates CD20 and enhances anti-CD20 antibody efficacy in B-cell precursor acute lymphoblastic leukemia.

It is demonstrated that overexpression of wild-type IKZF1, a tumor suppressor frequently mutated in high-risk BCP-ALL, upregulates CD20 and promotes leukemic B cell maturation, and the use of mTORC1 inhibitors to sensitize BCP-ALL cells to CD20-directed immunotherapies is supported.

Agnieszka Dąbkowska, Martyna Janowska, Agata Pastorczak et al. · Leukemia · 0 citations